Borhani N O
Cardiovascular Health Study, Carnelian Bay, California 96140.
Health Rep. 1994;6(1):76-86.
Results of all major clinical trials on the efficacy of treatment of hypertension provide convincing evidence that judicious treatment of hypertension in a clinical setting and effective control of hypertension in a community setting significantly reduce the rate of morbidity and mortality from stroke. It is especially noteworthy to review the results of some of the trials on prevention of stroke mortality in the elderly. HDFP: Antihypertensive drug treatment reduced the incidence of stroke among the HDFP cohort in the age group 60-69 years as significantly as it did in the younger age group. SHEP: Treatment of isolated systolic hypertension (ISH) reduced the incidence of stroke in the SHEP cohort by 36% in five years. MRC Trial: Similar results were reported by the follow-up of the cohort enrolled in the MRC Trial. The Swedish Study: Antihypertensive treatment reduced significantly the incidence of stroke in this cohort as well.
所有关于高血压治疗疗效的主要临床试验结果都提供了令人信服的证据，即在临床环境中明智地治疗高血压以及在社区环境中有效控制高血压可显著降低中风的发病率和死亡率。特别值得回顾一些关于老年人中风死亡率预防试验的结果。高血压检测与随访计划（HDFP）：降压药物治疗使HDFP队列中60 - 69岁年龄组的中风发病率降低程度与较年轻年龄组一样显著。收缩期高血压计划（SHEP）：单纯收缩期高血压（ISH）的治疗使SHEP队列中的中风发病率在五年内降低了36%。医学研究委员会（MRC）试验：对MRC试验入组队列的随访也报告了类似结果。瑞典研究：降压治疗也显著降低了该队列中的中风发病率。
